Patents Represented by Attorney Wendy L. Washtien
-
Patent number: 6894038Abstract: The invention relates to the use of esters of estriol, for example, an estriol 3,17-dipropionate or an estriol 3,17-dihexanoate, for the treatment of autoimmune diseases, such as multiple sclerosis (MS).Type: GrantFiled: February 27, 2003Date of Patent: May 17, 2005Assignee: Schering AktiengesellschaftInventors: Walter Elger, Sybille Beier, Harald Von Keyserlingk, Frank Dahlke
-
Patent number: 6855714Abstract: The invention relates to novel benzimidazole derivatives with general formula I, whereby radicals R1, R2, R3, A, B and Y have the meanings that are indicated in the description and the claims, the use of these compounds for the production of a pharmaceutical agent for treating and for preventing diseases that are associated with microglia activation, as well as pharmaceutical preparations that contain these compounds.Type: GrantFiled: July 5, 2002Date of Patent: February 15, 2005Assignee: Schering AktiengesellschaftInventors: Thorsten Blume, Wolfgang Halfbrodt, Joachim Kuhnke, Ursula Moenning, Herbert Schneider, Bernd Elger
-
Patent number: 6790828Abstract: The present invention relates to the design, production and use of analogs of thrombomodulin (TM) that have the ability to enhance the thrombin-mediated activation of protein C but which have a significantly reduced ability to promote activation of thrombin-activatable fibrinolysis inhibitor (TAFI). These analogs are useful in, for example, antithrombotic therapy.Type: GrantFiled: May 14, 2003Date of Patent: September 14, 2004Assignee: Schering AktiengesellschaftInventors: David Light, Michael John Morser, Mariko Nagashima
-
Patent number: 6682902Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.Type: GrantFiled: December 7, 2000Date of Patent: January 27, 2004Assignee: Schering AktiengesellschaftInventors: Richard Harkins, Deborah Parkes, Gordon Parry, Douglas W. Schneider, Renate Steinbrecher
-
Patent number: 6682896Abstract: The present invention discloses synthetic peptides and antibodies raised thereto wherein the synthetic peptides represent important epitopic sites recognized by monoclonal antibodies which can neutralize IFN-&bgr;. Also, the uses of these peptides or antibodies thereto as diagnostics and therapeutics are disclosed.Type: GrantFiled: June 2, 1995Date of Patent: January 27, 2004Assignee: Schering AktiengesellschaftInventor: Paul D. Hoeprich, Jr.
-
Patent number: 6632791Abstract: The present invention relates to the design, production and use of analogs of thrombomodulin (TM) that have the ability to enhance the thrombin-mediated activation of protein C but which have a significantly reduced ability to promote activation of thrombin-activatable fibrinolysis inhibitor (TAFI). These analogs are useful in, for example, antithrombotic therapy.Type: GrantFiled: June 12, 2001Date of Patent: October 14, 2003Assignee: Schering AktiengesellschaftInventors: David Light, Michael John Morser, Mariko Nagashima
-
Patent number: 6472172Abstract: The present invention relates to novel human inhibitor-of-apoptosis polypeptides, designated HIAP3, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.Type: GrantFiled: July 31, 1998Date of Patent: October 29, 2002Assignee: Schering AktiengesellschaftInventors: Gang Deng, Jiing-Huey Lin, Michael John Morser
-
Patent number: 6010864Abstract: The present invention discloses synthetic peptides and antibodies raised thereto wherein the synthetic peptides represent important epitopic sites recognized by monoclonal antibodies which can neutralize IFN-.beta.. Also, the uses of these peptides or antibodies thereto as diagnostics and therapeutics are disclosed.Type: GrantFiled: August 11, 1998Date of Patent: January 4, 2000Assignee: Schering AktiengellschaftInventor: Paul D. Hoeprich, Jr.
-
Patent number: 5985562Abstract: Polymorphisms within a plasma carboxypeptidase designated plasma carboxypeptidase B (PCPB) have been identified. The relative distribution of these polymorphs in a patient's blood can be used to assess an individual's risk toward thrombotic disease.Type: GrantFiled: June 3, 1997Date of Patent: November 16, 1999Assignee: Schering AktiengesellschaftInventors: Michael John Morser, Mariko Nagashima
-
Patent number: 5863760Abstract: The present invention relates to the single-chain thrombomodulin ("TM") and analogs thereof that are not susceptible to cleavage by proteases and retain the biological activity of thrombomodulin, as well as methods of use in, for example, antithrombotic therapy. Novel proteins, nucleic acid gene sequences, pharmaceuticals and methods of inhibiting thrombotic activity are disclosed.Type: GrantFiled: June 5, 1995Date of Patent: January 26, 1999Assignee: Schering AltiengesellschaftInventors: David Richard Light, William H. Andrews, Jeffrey Homer Clarke, Robert Michael Wydro, Patricia Ann Young
-
Patent number: 5840687Abstract: The invention provides for synthetic ligands that bind to class I receptor tyrosine kinases. The ligands are analogous in structure to naturally occurring ligands. The modified ligands however, have eliminated the mid-sequence (B) domain present in the native ligands and replaced it with a peptide bridge which links the amino (A) and carboxy (C) domains.Type: GrantFiled: February 2, 1995Date of Patent: November 24, 1998Assignee: Schering AktiengesellschaftInventors: Richard N. Harkins, Marian Seto, Bradley A. Katz
-
Patent number: 5827824Abstract: The present invention relates to the single-chain thrombomodulin ("TM") and analogs thereof that are not susceptible to cleavage by proteases and retain the biological activity of thrombomodulin, as well as methods of use in, for example, antithrombotic therapy. Novel proteins, nucleic acid gene sequences, pharmaceuticals and methods of inhibiting thrombotic activity are disclosed.Type: GrantFiled: June 5, 1995Date of Patent: October 27, 1998Assignee: Schering AktiengesellschaftInventors: David Richard Light, William H. Andrews, Jeffrey Homer Clarke, Robert Michael Wydro, Patricia Ann Young
-
Patent number: 5731186Abstract: rDSPA .alpha.1 is produced in commercial quantities and a purity adequate for clinical standards. The production methods utilize a series of chromatographic steps: cation exchange chromatography, followed by hydrophobic interaction chromatography, and ending with affinity chromatography.Type: GrantFiled: February 5, 1996Date of Patent: March 24, 1998Assignee: Schering AktiengesellschaftInventors: Michael McCaman, Erno Pungor, Carol Souders, Mei P. Tan
-
Patent number: 5702931Abstract: Methods and reagents for oligonucleotide-directed mutagenesis of a target nucleic acid are provided. In these methods a mutagenic oligonucleotide introduces a desired mutation at one site and, at a second site, introduces or eliminates a restriction site, allowing one to screen for the desired mutation by restriction analysis. Also provided are vectors and kits for performing such mutagenesis methods.Type: GrantFiled: December 28, 1993Date of Patent: December 30, 1997Assignee: Berlex Laboratories, Inc.Inventors: William H. Andrews, Michael J. Morser, Laura R. Vilander
-
Patent number: 5578310Abstract: A topical bioadhesive ointment composition comprising an aqueous mineral oil emulsion which is readily spread able and film-forming, and, upon application to moist skin or a mucosal surface, forms a stable, coherent layer thereon which resists removal therefrom by water or a body fluid associated with the mucosal surface to which the ointment composition is applied is disclosed. Also disclosed are pharmaceutical compositions containing the ointment compositions and a pharmaceutically active agent, e.g. , TGF.alpha.; and methods of using and methods of preparing the compositions.Type: GrantFiled: June 3, 1994Date of Patent: November 26, 1996Assignee: Berlex Laboratories Inc.Inventors: Thabiso M'Timkulu, Ze'ev Shaked, Richard Hsu